Clinical Immunology of Multiple Sclerosis

Multiple sclerosis is an immune-mediated disorder characterised by inflammatory demyelination and neurodegeneration within the central nervous system. A breakdown of the blood–brain barrier permits autoreactive T cells, particularly T helper 1 and T helper 17 subsets, to infiltrate perivascular spaces, where they interact with antigen-presenting cells and B lymphocytes. B cells contribute both as antibody producers and as antigen presenters, forming ectopic lymphoid structures in meninges that correlate with progressive cortical injury. Cytokine networks involving interferon-γ, tumour necrosis factor and interleukin-17 drive lesion formation and microglial activation. Contemporary therapies—ranging from B-cell-depleting monoclonal antibodies to sphingosine-1-phosphate modulators—target distinct checkpoints in this immunopathology, aiming to reduce relapse frequency and slow disability accrual. Emerging work integrates neuroendocrine factors into this framework, expanding potential targets for barrier protection and immune regulation.

Research from Nature Portfolio

Recent studies have revealed that neurohypophyseal peptides modulate barrier integrity and neuroinflammation. In experimental autoimmune encephalomyelitis models, pharmacological blockade of vasopressin V1a and V2 receptors restored tight-junction protein expression, markedly reduced perivascular cuffing and attenuated clinical scores. These findings position neuroendocrine antagonists as adjuncts to classical immunosuppression and highlight the interplay between endocrine mediators and central immune surveillance.

Clinical Immunology of Multiple Sclerosis publication trend

The graph below shows the total number of articles in clinical immunology of multiple sclerosis across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): A specialised endothelial interface that restricts passage of cells and molecules between the circulation and central nervous system.

Experimental autoimmune encephalomyelitis (EAE): An animal model of central nervous system demyelination induced by immunisation with myelin antigens, used to study multiple sclerosis pathogenesis.

Vasopressin receptor antagonist: A pharmacological agent that blocks vasopressin receptors (V1a, V2), reducing peptide-mediated changes in vascular permeability and inflammation.

Interferon-γ release assay: A blood test measuring interferon-γ production by immune cells in response to antigenic stimulation, used to assess functional capacity of the immune system.

B-cell-depleting therapy: Monoclonal antibody treatment targeting CD20 or other B-cell markers to reduce pathogenic antibody production and antigen presentation.

References

1. Blockade of Arginine Vasopressin receptors prevents blood-brain barrier breakdown in Experimental Autoimmune Encephalomyelitis. Scientific Reports (2020).
2. Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment. Frontiers in Neuroscience (2023).
3. Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor. Journal of Immunology Research (2023).